34 related articles for article (PubMed ID: 8584609)
1. Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D
Whiting RL; Darpo B; Chen C; Fletcher M; Combs D; Xue H; Stoltz RR
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):927-939. PubMed ID: 33462988
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of the dopamine D1 antagonist, NNC 01-0687, on unstimulated and stimulated release of anterior pituitary hormones in males.
Grodum E; Andersen M; Hangaard J; Koldkjaer O; Hagen C
J Endocrinol Invest; 1998 May; 21(5):291-7. PubMed ID: 9648050
[TBL] [Abstract][Full Text] [Related]
3. D1 receptor antagonists in schizophrenia.
Barnes TR; Gerlach J
Psychopharmacology (Berl); 1995 Oct; 121(3):287-8. PubMed ID: 8584607
[No Abstract] [Full Text] [Related]
4. Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects.
Skrumsager BK; Christensen JV; Snel S; Seiberling M
Psychopharmacology (Berl); 1995 Oct; 121(3):294-9. PubMed ID: 8584609
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of NNC 756--a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man.
Karlsson P; Farde L; Halldin C; Sedvall G; Ynddal L; Sloth-Nielsen M
Psychopharmacology (Berl); 1995 May; 119(1):1-8. PubMed ID: 7675940
[TBL] [Abstract][Full Text] [Related]
6. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756.
Abi-Dargham A; Simpson N; Kegeles L; Parsey R; Hwang DR; Anjilvel S; Zea-Ponce Y; Lombardo I; Van Heertum R; Mann JJ; Foged C; Halldin C; Laruelle M
Synapse; 1999 May; 32(2):93-109. PubMed ID: 10231129
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H; Gerlach J; Mørkeberg F
Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
[TBL] [Abstract][Full Text] [Related]
8. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
9. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity.
Gerlach J; Hansen L
J Psychopharmacol; 1993 Jan; 7(4):355-64. PubMed ID: 22290999
[TBL] [Abstract][Full Text] [Related]
10. Animal models with construct validity for schizophrenia.
Ellenbroek BA; Cools AR
Behav Pharmacol; 1990; 1(6):469-490. PubMed ID: 11175433
[TBL] [Abstract][Full Text] [Related]
11. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor.
Karlsson P; Farde L; Halldin C; Swahn CG; Sedvall G; Foged C; Hansen KT; Skrumsager B
Psychopharmacology (Berl); 1993; 113(2):149-56. PubMed ID: 7855175
[TBL] [Abstract][Full Text] [Related]
12. SCH 23390 - the first selective dopamine D-1 antagonist.
Hyttel J
Eur J Pharmacol; 1983 Jul; 91(1):153-4. PubMed ID: 6225651
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
